Researchers have discovered a new way to improve immunotherapy by using genomics to inform immunotherapy treatments for multiple myeloma, according to the findings of a study published in Clinical Cancer Research.
In this study, researchers from the Icahn School of Medicine at Mount Sinai Next-generation sequencing analyzed neoantigens in 184 patients and identified neoantigen-specific immune cells triggered by immunotherapy.
Their findings suggest an increase in neoantigens in patients who had relapsed myeloma versus new patients, which may indicate potential for greater immune responses to immunotherapy in these patients. The study also identifies common neoantigens between patients, which could lead to new vaccine therapies.
https://twitter.com/thedextazlab/status/1207707684515958787
This marked the first study that sought to determine which tumor mutation byproducts possess the ability to provoke the immune system into recognizing and killing cancer cells in multiple myeloma patients. “Tumor neoantigens represent excellent targets for immunotherapy, due to their specific expression in cancer tissue,” said Samir Parekh, MD, Associate Professor of Oncological Sciences and Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine in a press release about the study.
“Until now, there has been no direct evidence that DNA mutations induce neoantigen-specific T-cell responses following immunotherapy in multiple myeloma.”
Researchers Identify Potential Formula for Blood Cancer Vaccine: Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way to move precision immunotherapy forward by using genomics to inform immunotherapy for multiple myeloma a… https://t.co/JlmOvthzdE
— Renal Cell Carcinoma (@Renal_Bio) December 19, 2019
Researchers identify potential formula for blood cancer vaccine https://t.co/3RkwTMpdEB pic.twitter.com/m9L2RkwPr5
— Krishan Maggon (@kkmaggon) December 19, 2019
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.